Press Releases Year None202620252024202320222021202020192018 May 06, 2026 Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update Apr 07, 2026 Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference Mar 23, 2026 Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Mar 18, 2026 Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Feb 24, 2026 Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Feb 11, 2026 Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines Feb 10, 2026 Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 Feb 05, 2026 Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit Feb 02, 2026 Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Jan 29, 2026 Vaxcyte Announces Pricing of $550 Million Public Offering Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
Year None202620252024202320222021202020192018 May 06, 2026 Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update Apr 07, 2026 Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference Mar 23, 2026 Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Mar 18, 2026 Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Feb 24, 2026 Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Feb 11, 2026 Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines Feb 10, 2026 Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 Feb 05, 2026 Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit Feb 02, 2026 Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Jan 29, 2026 Vaxcyte Announces Pricing of $550 Million Public Offering Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
